Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Neurocrine picks Takeda’s brain
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Go or no go? Oncology dominates upcoming decisions
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
Go or no go? Covid-19 upstages US regulatory decisions
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Upcoming events – Avadel takes on Jazz and Axovant awaits early results
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
